Popular Trials
Kinase Inhibitor
Tepotinib for Lung Cancer
Recruiting1 awardPhase 2
Duarte, California
This trial will study the effects of tepotinib on lung cancer growth and spread, as well as safety, side effects, and quality of life. Pharmacogenetic research may also be conducted to study how genes impact the effectiveness of the drug.
Enzyme Inhibitor
Telotristat Etiprate for Neuroendocrine Neoplasm
Recruiting1 awardPhase 2
Detroit, Michigan
This trial is testing how well telotristat etiprate works in treating neuroendocrine neoplasm. Telotristat etiprate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying the changes within the tumor cells may help doctors better understand how tumors respond to treatment with telotristat etiprate.
Popular Filters
Trials for MPN Patients
Anti-metabolite
Azacitidine + Quizartinib for Myelodysplastic Syndrome
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing the side effects and best dose of quizartinib when given with azacitidine to people with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL mutations.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
INCB057643 +/- Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1
Birmingham, Alabama
This trial is testing a new drug called INCB057643, alone or with ruxolitinib, for patients with certain blood cancers like myelofibrosis. The goal is to see if it can stop cancer growth or help other treatments work better. Ruxolitinib has been approved for the treatment of myelofibrosis and has shown clinical benefits in reducing symptoms and improving survival.
Bcl-2 Inhibitor
Navitoclax + Ruxolitinib for Myeloproliferative Disorders
Recruiting1 awardPhase 1
Los Angeles, California
This trial has 4 parts to evaluate the safety and how well the drug navitoclax works when given alone or with another drug, ruxolitinib. The trial will also look at how navitoclax affects QTc prolongation and how it affects the PK, safety, and tolerability of celecoxib in people with MPN or CMML.
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
Recruiting1 awardPhase 1 & 2
Orange, California
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Trials for Acute Myelogenous Leukemia Patients
Targeted Therapy
SL-401 + Azacitidine/Venetoclax for AML and MDS
Recruiting1 awardPhase 1
Duarte, California
This trial is studying how well SL-401, azacitidine, and venetoclax work in treating patients with acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, or high-risk myelodysplastic syndrome.
CAR T-cell Therapy
Genetically Modified T-cell Therapy for Leukemia
Recruiting1 awardPhase 1
Duarte, California
This trial is testing the side effects and best dosage of genetically modified T-cells, which are a type of immune cell, in patients with leukemia or a certain type of cancer of the blood and bone marrow.
Anti-metabolite
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing two drugs, ruxolitinib phosphate and azacytidine, in patients with specific types of blood cancers that are hard to treat. Ruxolitinib blocks enzymes needed for cancer cell growth, while azacytidine kills cancer cells or stops them from dividing. Azacytidine is a well-known anticancer drug used in the treatment of various cancers, including breast cancer, melanoma, and colon cancer. The goal is to find a more effective treatment for these patients.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
Recruiting1 awardPhase 2
Seattle, Washington
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Topoisomerase Inhibitor
CPX-351 vs CLAG-M for Acute Myeloid Leukemia
Recruiting1 awardPhase 2
Seattle, Washington
This trial is studying CPX-351 or the CLAG-M regimen to see how well they work in treating patients with acute myeloid leukemia or other high-grade myeloid neoplasms who are not physically fit enough for standard doses of CPX-351.
Trials With No Placebo
Behavioral Intervention
Serious Gaming for Nausea and Vomiting
Recruiting1 award3 criteria
Miami, Florida
"This trial aims to see if a technology-based approach can help older adults with cancer better manage nausea and vomiting. Participants will be divided into two groups - one receiving the intervention and the other not. The
Virus Therapy
G207 + Radiation for Pediatric Brain Tumor
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial tests a new treatment for children with aggressive brain tumors that haven't responded to other treatments. The treatment uses a special virus injected into the tumor, followed by a small dose of radiation. The virus kills cancer cells and helps the immune system fight the tumor.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.